Property:Specifications on cancer therapies
This is a property of type Text.
A
Afonseca et al. (2013): Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: A pilot randomized clinical trial +
Oxaliplatin-based chemotherapy
+ calcium and magnesium supplements before and after oxaliplatin infusions +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
Oral or injection chemotherapy was administered to the patients according to the stage, except in stage IA and tumor size less than 2 cm +
Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy +
Chemotherapy regimens (n intervention vs. placebo arm):
- AC, i.e. doxorubicin60 mg/m2 +cyclophosphamid 600 mg/m<sup>2</sup> (41 vs. 44)
- CAF, i.e. cyclophosphamide 500mg/m2 + doxorubicin 50mg/ m<sup>2</sup> + 5-Fluorouracil 500mg/m<sup>2</sup> (19 vs. 18)
- TAC, i.e. docetaxel 75mg/m<sup>2</sup> + doxorubicin 50mg/m<sup>2</sup> + cyclophosphamide 500mg/m<sup>2</sup> (15 vs. 13) +
Regimen: FOLFIRI, Oxaliplatinum based or 5 FU-based +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
Chemotherapy treatment by a regimen including cyclophosphamide, doxorubicin, dacarbazine, gemcitabine, methotrexate, and 5-fluorouracil +
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results +
Cisplatin-based chemotherapy +
Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation +
Paclitaxel-based chemotherapy +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
Chemotherapy with adjuvant anthracycline (chemotherapy protocols: anthracycline, cyclophosphamide, doxorubicin, and 5-fluorouracil), no significant differences between arms in chemotherapy characteristics (p > 0.05) +
Asfour et al. (2006): Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients +
Combination chemotherapy composed of cyclophosphamide doxorubicin, oncovine, and prednisone (CHOP), treatment consisted of sisted of 750 mg/m2 on first day of the treatment cycle intravenously (IV) cyclophosphamide, 50 mg/m2 IV doxorubicin, 1.4 mg/m2 IV vincristine, and 100 mg po days 1 to 5 prednisone; chemotherapy cycles were repeated every 28 days +
Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer +
Docetaxel was supplied commercially. Patients received, on a 28-day cycle, 35 mg/m<sup>2</sup> docetaxel i.v. on days 1, 8, and 15 over 1 hour +
Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis +
NI +
B
Bairati et al. (2005): A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients +
NA +
Bairati et al. (2005): Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients +
NA +
Bairati et al. (2006): Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients +
NA +
Barton et al. (1998): Prospective evaluation of vitamin E for hot flashes in breast cancer survivors +
Tamoxifen use in 59% (intervention arm) and 60% (placebo arm) +
Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9 +
All patients chemotherapy (Intervention/ placebo arm):
Doxorubicin/cyclophosphamide 35 (33 %)/ 37 (36 %)
Doxorubicin/cyclophosphamide/taxane 56 (52 %)/ 54 (52 %)
Other anthracycline-based chemo 6 (6 %)/ 0 (0 %)
Other nonanthracycline-based chemo 10 (9 %)/ 12 (12 %)
Adjuvant Tamoxifen therapy planned (intervention/ placebo arm):
Yes 55 (51 %)/ 56 (54 %)
No 52 (49 %)/ 47 (46 %) +
Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators +
Weekly docetaxel 36 mg/m<sup>2</sup> intravenously and dexamethasone (4 mg orally 12 hours before, 1 hour before, and 12 hours after docetaxel administration) +
Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin +
HEC with cisplatin (single dose >50 mg/m2 every 21 or 28 day +
Braga et al. (2015): Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer +
Chemotherapy regimen: CAPOX (capecitabine + oxaliplatin), Capecitabine or 5-fluorouracil + folinic acid +
Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy +
Chemotherapy with capecitabine
Capecitabine alone (n = 43)
Capecitabine + oxaliplatin (n = 24)
Capecitabine + lapatinib (n = 5)
Capecitabine + trastuzumab (n = 3)
Capecitabine + cetuximab (n = 2) +